Should Myriad Genetics Stock Stay in Your Portfolio Right Now?

Myriad Genetics (market cap $604.3M) is pursuing multiple product launches (Prequel Prenatal Screen, Foresight Carrier Screening, Precise Tumor, upcoming MyRisk with RiskScore) and strategic partnerships (PATHOMIQ, SOPHiA GENETICS) aimed at driving growth across the Cancer Care Continuum, while exiting Q3 2025 with $145.4M cash and no current debt. Offsetting those positives, UnitedHealthcare’s Nov. 1, 2024 termination of coverage for GeneSight has materially pressured pharmacogenomics revenue, Zacks’ 2025 revenue consensus is $821.5M (‑1.9% YoY), and the stock has declined ~53.7% over the past year, leaving the story balanced between operational upside and near-term reimbursement and macro risks.

Analysis

Market structure: Myriad (MYGN) is a bifurcated story — product launches (Prequel, Precise Tumor, expanded MyRisk) give upside to test-volume and therapy-selection TAMs ($6B hereditary cancer market), while UnitedHealthcare’s GeneSight delisting compresses near-term pharmacogenomics revenue and sentiment. Competitors with scale sequencing (ILMN) retain pricing power on platform reagents; niche players (SOPH partnership beneficiaries) can win CDx contracts. Reagent/labor inflation and tariffs tighten gross margin levers and test supply elasticity, keeping throughput pricing pressure in 12–24 months.

Risk assessment: Tail-risks include cascading payer denials (if 3–5 large national plans follow UHC within 3–6 months), FDA/CLIA setbacks on new assays, or PATHOMIQ/SOPHiA execution failure — each could drive >30% downside from current levels. Short-term (days–weeks) volatility will track earnings/payer headlines; medium-term (quarters) depends on commercial uptake and reimbursement; long-term (12–36 months) hinges on MyRisk/RiskScore adoption and margin recovery. Hidden dependency: sample-shipping/logistics and reagent chip supply; a single vendor disruption could bottleneck volume.

Trade implications: Tactical size and instruments matter — favor a capped-risk long exposure to MYGN (2–3% portfolio) via long-dated call spreads (9–12 month) to play product cadence while limiting capital at risk; keep a 25% stop if sequential revenue falls >10% vs guidance. Maintain a contingent short (1–2% notional) via 3-month puts if two additional major payers announce noncoverage within 60 days or if next quarter guidance cuts >5% YoY. Rotate modestly out of expensive sequencing leaders into select diagnostics names with clear payer pathways (trim ILMN by 1–2% if multiples remain >25x).

Contrarian angle: Consensus discounts MYGN’s pipeline and cash runway — company has $145M cash and no debt, so M&A or recovery-driven rerating is plausible if MyRisk gains clinical/payer traction in 12–18 months. The market may be over-pricing permanent revenue loss from GeneSight; historically (similar payer skews in diagnostics), companies recovered ~40–60% of lost revenue within 12–24 months via new product uptake and contracting. Upside catalyst sequence to watch: positive PATHOMIQ validation, two payer reinstatements or strong MyRisk early-access adoption; absence of these would validate downside.

Key Decisions for Investors

• Establish a tactical long in MYGN equal to 2–3% of portfolio via a 9–12 month call spread (buy 0–30% OTM call, sell 30–60% OTM call) to capture product-launch upside while capping premium; add only if next 30-day price does not gap down >15%.
• Initiate a contingent protection/short: purchase 3-month puts (size 1–2% notional) or short shares if two additional large national payers announce GeneSight-like noncoverage within 60 days or if management cuts FY revenue guide >5% on next quarterly call.
• Trim 1–2% exposure to high-multiple sequencing leaders (e.g., ILMN) and redeploy into select diagnostics/radiology/precision-medicine names with clearer near-term reimbursement paths; re-evaluate after the next two earnings seasons.
• Monitor specific catalysts: (a) PATHOMIQ/SOPHiA validation data (within 90 days), (b) MyRisk commercial roll-out metrics and early-access volumes (next 6–12 months), and (c) payer policy changes from UnitedHealthcare peers — act decisively on any one showing material divergence (>5% revenue implication).